Aesica recruits Technical Director to create global Lead Technical Centres for API development, drug product development and technology innovation.
The appointment of Bashir Hansraj marks an important step towards delivering the Aesica vision of being the number one supplier of API and formulated products to the pharmaceutical industry.
"The creation of Lead Technical Centres will enhance the technical expertise and services we will offer to our customers. We aim to provide creative solutions for the challenges of drug lifecycle management throughout the continuum of preclinical development through to post patent expiration" Bashir Hansraj, Global Technical Director at Aesica
9 July 2013 - Newcastle: Aesica, the global development and contract manufacturing organisation (CDMO), has pushed ahead with the next stage in its technical and innovation strategy with the appointment of a Global Technical Director, Bashir Hansraj, responsible for developing lead technical centres across the entire international Aesica network from API and drug product development sites right through to finished product manufacturing and packaging.
Based at Aesica headquarters in Newcastle (UK), Hansraj will lead and direct the company's global technical and innovation strategy across the full spectrum of API and dosage form development. Technical centres will be dedicated to specific dosage forms including; oral solids, oral liquids, topicals, inhalation and parenterals.
With over 30-years' experience in the pharmaceutical industry and having held senior management R&D positions - within Pfizer Consumer Healthcare, J&J, Pfizer Global R&D and most recently at Catalent where he was head of Research and Development - Hansraj brings a depth of technical expertise and business acumen in new product development and technology transfer for pre-proof of concept to post launch assets on a global scale. In addition to Life Science degrees he also has an MBA and, in his previous roles, led the development and commercialisation of many leading OTC and Rx brands utilising many technology platforms .
Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world's leading pharmaceutical companies and emerging biotechnology organisations.
The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.
· Aesica is one of the UK's fastest growing companies and over the last five years has more than trebled its turnover.
· The company currently employs approximately 1,300 people.
· In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy. It also has sales representation in San Diego and Shanghai.
· The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: +44 (0) 20 7203 6740/6745 or e-mail; [email protected].